Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot study
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Mehmet Kayrak Ahmet Bacaksiz Mehmet S. Ulgen Mehmet Akif Vatankulu Kadriye Zengin Selim S. Ayhan Mustafa Kemal Basaral Sadik Bu¨yu¨kbas
- چاپ و سال / کشور: 2010
Description
Coronary artery disease (CAD) is believed to be the single leading cause of death in both men and women in the world. Smoking is the most important risk factor for CAD. Smoking increases platelet aggregation and thrombus formation. CD40 ligand (CD40L) is a transmembrane glycoprotein derived from activated platelets. It participates in thrombus formation during the acute phase of acute myocardial infarction (MI). Elevation of CD40L identifies the patients who are at highest risk for cardiac events and who are likely to benefit from treatment with the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonists. The purpose of this study was to evaluate levels of CD40L in smokers with acute MI. Fifty-seven patients with acute MI were enrolled in this study. Thirty-one smokers were compared with 26 non-smokers. Soluble CD40L level in the plasma was determined by a standard enzyme-linked immunosorbent assay. Circulating levels of CD40L were higher in the smokers’ group. Smokers with acute MI may have increased risk for thrombotic complications during acute MI, and optimal antiaggregant therapy should be administered.
Heart Vessels (2011) 26:131–137 DOI 10.1007/s00380-010-0036-x Received: 5 February 2009 / Accepted: 25 February 2010 / Published online: 27 October 2010
